Patent License Agreement Mexico (Contrato de Licencia de Patente)

A Patent License Agreement Mexico (Contrato de Licencia de Patente) is a written contract governed by Articles 64 through 79 of the Ley Federal de Protección a la Propiedad Industrial (LFPPI, published in the Diario Oficial de la Federación on 1 July 2020) by which the owner of a Mexican patent (patentee or licenciante) grants a third party (licensee or licenciatario) the right to exploit the patented invention — including manufacturing (fabricar), using (usar), selling (vender), offering for sale (ofrecer en venta), or importing (importar) products or processes embodying the invention — within defined conditions of territory, field of use, duration, and royalty payment, without transferring title to the patent.

Patent rights in Mexico arise from registration with the Instituto Mexicano de la Propiedad Industrial (IMPI) — the federal agency created by Decreto published in the DOF on 10 December 1993, which administers Mexico's patent, utility model, industrial design, and trademark systems. Under Articles 45 through 63 LFPPI, IMPI grants patents for inventions that satisfy the three patentability requirements (requisitos de patentabilidad): novelty (novedad) — the invention must not have been disclosed anywhere in the world before the filing date; inventive step (actividad inventiva) — the invention must not be obvious to a person skilled in the art; and industrial application (aplicación industrial) — the invention must be capable of industrial production or use. Mexican patents granted under the current LFPPI confer a 20-year non-renewable protection term from the patent application filing date, consistent with Article 33 of the TRIPS Agreement.

The Contrato de Licencia de Patente Mexico operates within the framework of the T-MEC (Tratado entre México, Estados Unidos y Canadá — CUSMA/USMCA) Chapter 20 on Intellectual Property, which sets minimum standards for patent protection and licensing in Mexico. Mexico is also a member of the Patent Cooperation Treaty (PCT — Tratado de Cooperación en materia de Patentes), administered by the Organización Mundial de la Propiedad Intelectual (OMPI/WIPO) — PCT applications designating Mexico enter the national phase before IMPI and, upon grant, are subject to the same licensing framework under Articles 64–79 LFPPI as domestically filed patents.

The distinction between a patent license and a patent assignment is fundamental in Mexican IP law. Under Articles 64–79 LFPPI, a licencia de patente grants exploitation rights while the patentee retains ownership of the patent registration. Under Articles 80–83 LFPPI (cesión de patente), an assignment permanently transfers ownership of the patent to the assignee. A patent license may be exclusive (exclusiva) — where only the licensee and potentially the patentee can exploit the invention in the licensed field and territory — or non-exclusive (no exclusiva) — where the patentee may grant simultaneous licenses to multiple parties. Article 65 LFPPI requires that patent licenses be recorded (inscritos) with IMPI to be enforceable against third parties (oponibles a terceros). IMPI maintains the Registro de Patentes, which is publicly accessible and allows third parties to verify the existence of recorded licenses before engaging with a patent holder or licensee.

Article 70 LFPPI establishes compulsory licensing (licencias obligatorias or de utilidad pública) — in exceptional circumstances involving public health emergencies, national security, or non-working of the patent for three consecutive years, the Mexican government or an interested third party may petition IMPI or the relevant ministry for a compulsory license to exploit the patent without the patentee's consent, subject to payment of reasonable compensation. This provision was highlighted during the COVID-19 pandemic when Mexico's Decreto published in 2020 facilitated compulsory licenses for health technologies.

A Patent License Agreement Mexico is required whenever the owner of a Mexican patent wishes to authorize a third party to exploit the patented invention commercially without transferring ownership of the patent registration. The Contrato de Licencia de Patente is the primary vehicle for technology transfer (transferencia de tecnología) in Mexico's industrial, pharmaceutical, agricultural, and technology sectors.

Manufacturing licenses are needed when a foreign patent holder — such as a multinational pharmaceutical company, industrial equipment manufacturer, or technology developer — wishes to authorize a Mexican manufacturer (fabricante) to produce patented products in Mexico for domestic sale or export. The license formalizes the technology transfer, specifies quality standards, and establishes royalty payment structures compliant with SAT transfer pricing requirements under LISR Articles 179–184E.

Distribution and sales licenses are required when a patent holder wishes to authorize a Mexican company to import, sell, and offer for sale patented products in Mexico without manufacturing rights — giving the licensee commercial access to the Mexican market while the patentee controls manufacturing elsewhere. The distribution license must expressly authorize the specific acts of exploitation covered (import, sale, offering for sale) under Article 64 LFPPI.

Cross-licensing agreements are used in technology-intensive industries — including semiconductors, telecommunications, and automotive manufacturing — where multiple companies hold complementary patent portfolios and grant each other mutual licenses to avoid infringement claims. Mexico's automotive manufacturing sector, centered in Guanajuato, Nuevo León, and Puebla, involves extensive patent cross-licensing between Tier 1 suppliers and OEMs.

Research and development licenses allow universities (universidades) and research institutions — including CONACYT-funded centers such as the Centro de Investigación y de Estudios Avanzados (CINVESTAV) and CIATEC — to license patented research tools and platform technologies to commercial companies for further development and commercialization. The Ley de Ciencia y Tecnología (LCyT) encourages technology transfer from publicly funded research to industry.

Franchise technology licensing frequently incorporates patent licenses alongside trademark licenses under Article 142 LFPPI when the franchise system involves patented processes or equipment. The Contrato de Licencia de Patente is executed alongside the franchise agreement to authorize the franchisee's use of patented systems in the franchised operation.

Agricultural biotechnology companies developing plant variety protection and patented seed technologies for Mexico's commercial agricultural sector — including drought-resistant corn (maíz resistente a la sequía), high-yield sorghum, and protected vegetable seed varieties — require patent license agreements to govern the distribution of licensed seed to growers, restricting replanting and establishing royalty collection mechanisms under LFPPI Articles 64–79 and the Ley Federal de Variedades Vegetales administered by SAGARPA (now SADER).

A Patent License Agreement Mexico compliant with LFPPI Articles 64–79 must contain the following essential elements to adequately protect the licensor's patent rights while clearly defining the licensee's exploitation rights:

Identification of Parties and Patent: Full legal name, RFC, and domicilio of the licensor (licenciante) and licensee (licenciatario); the IMPI patent registration number (número de registro de patente); the patent title (título de la invención); the filing date (fecha de presentación) and grant date (fecha de concesión); and the remaining term of the patent protection (vigencia restante) — critical because Mexican patents cannot be renewed beyond the 20-year term from filing. For PCT patents in the Mexican national phase, the international application number and national phase entry date should also be specified.

Scope of License — Exclusive or Non-Exclusive: Whether the license is exclusive (exclusiva) or non-exclusive (no exclusiva) under Article 65 LFPPI. An exclusive patent license grants the licensee the sole right to exploit the invention in the defined field and territory — including to the exclusion of the patentee itself. Non-exclusive licenses allow the patentee to exploit the invention and grant additional licenses. The agreement should also address whether the licensee may grant sublicenses (sublicencias) — Article 68 LFPPI permits sublicensing only with the patentee's written authorization.

Field of Use: The specific technological or commercial field within which exploitation is authorized — for example, 'manufacture and sale of chemical compound X for use exclusively in agricultural applications' — when the patent covers multiple applications. Field-of-use restrictions allow the patentee to license different applications to different licensees and are expressly permitted under the T-MEC Chapter 20 framework, provided they do not unreasonably restrain competition.

Territory: The geographic territory within which the licensee may exploit the invention — the República Mexicana, specific states (entidades federativas), or specific product markets. The territory defines where the licensee may manufacture, sell, import, and offer for sale products covered by the patent claims (reivindicaciones de la patente).

Exploitation Rights Authorized: The specific exploitation acts authorized from the Article 64 LFPPI list — manufacture (fabricar), use (usar), sell (vender), offer for sale (ofrecer en venta), and/or import (importar) products covered by the patent claims. The agreement must identify precisely which acts are licensed to avoid disputes about the scope of the licensee's rights.

Royalties and Payment: The royalty structure — flat fee (tarifa fija), running royalty (regalía corriente) as a percentage of net sales of licensed products; milestone payments (pagos por hitos) for reaching development or commercial milestones; minimum annual royalties (regalías mínimas anuales) to maintain exclusivity. Currency, payment dates, late payment interest, and audit rights allowing the licensor to verify the licensee's sales records are essential commercial terms. Transfer pricing compliance under LISR Articles 179–184E requires arm's length royalty rates for intra-group patent licenses.

Improvement Inventions: Whether improvements (mejoras) made by the licensee to the licensed technology must be assigned or licensed back to the licensor (grant-back provisions). Mexican competition law under the Ley Federal de Competencia Económica (LFCE) Article 56 prohibits competition-restricting IP licensing conditions including exclusive grant-back requirements that compel the licensee to assign all improvements to the licensor — non-exclusive grant-back licenses are generally permissible.

IMPI Recordal: The obligation to record the license with IMPI under Article 65 LFPPI for third-party enforceability, identifying which party is responsible for the application, official fee payment under the Ley Federal de Derechos, and the target recordal timeline.

forms-legal.com provides this Patent License Agreement Mexico template as a practical starting point. Patent licenses involving significant technology value, pharmaceutical patents, or cross-border technology transfer arrangements should be reviewed by a Licenciado en Derecho specialised in propiedad industrial and by SAT-registered transfer pricing specialists.